•
US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali Medpharma. While the financial details of the deal remain undisclosed, this strategic move significantly expands Resolian’s bioanalysis laboratory capabilities to China, complementing its existing operations in the US, UK, and Australia. This expansion allows Resolian’s…